This study demonstrates that genetic polymorphisms CYP3A4*22 (rs35599367) and CYP3A5*3 (rs776746) are associated with significant differences in the Css min of silodosin in BPH patients, which may reflect altered drug exposure, although a full pharmacokinetic profiling (e.g., Cmax, Tmax, and Cl) was not conducted. This evidence concerns the gene CYP3A4 and benign prostatic hyperplasia.